Company: BLTE
Filing Date: 2025-01-27
Form Type: 424B7
Source: 0001104659-25-006367
Chunk: 21

Company: BELITE BIO, INC
Filing Date: 2025-01-27
Form: 424B7
Chunk 21
---
” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the 30 day prohibition period, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) any at-the-market offering conducted by the Company under an effective registration statement filed with the SEC.

#### Nasdaq Capital Market Listing
Our ADSs are listed on the Nasdaq Capital Market under the symbol “BLTE.” There is no established public trading market for the Warrants, and we do not expect one to develop. We do not intend to apply to list the Warrants on any securities exchange.

<div align='center'>S-15</div>

TABLE OF CONTENTS

### LEGAL MATTERS
We are being represented by O’Melveny & Myers LLP with respect to legal matters of U.S. federal securities and New York State law. The validity of the offered securities and certain other matters of Cayman Islands law will be passed upon for us by Maples and Calder (Hong Kong) LLP. O’Melveny & Myers LLP may rely upon Maples and Calder (Hong Kong) LLP with respect to matters governed by Cayman Islands law. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.

<div align='center'>S-16</div>

TABLE OF CONTENTS

### EXPERTS
The consolidated financial statements of Belite Bio, Inc at December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023 appearing in Belite Bio, Inc’s Annual Report (Form 20-F) for the year ended December 31, 2023, have been audited by Marcum Asia CPAs LLP, an independent registered public accounting firm, as set forth in their reports thereon incorporated herein by reference. Such financial statements are incorporated herein in reliance upon the reports of Marcum Asia CPAs LLP pertaining to such financial statements given on the authority of